165 related articles for article (PubMed ID: 24704786)
21. Tick-borne flavivirus NS5 antagonizes interferon signaling by inhibiting the catalytic activity of TYK2.
Gracias S; Chazal M; Decombe A; Unterfinger Y; Sogues A; Pruvost L; Robert V; Lacour SA; Lemasson M; Sourisseau M; Li Z; Richardson J; Pellegrini S; Decroly E; Caval V; Jouvenet N
EMBO Rep; 2023 Dec; 24(12):e57424. PubMed ID: 37860832
[TBL] [Abstract][Full Text] [Related]
22. Structural Analysis of Janus Tyrosine Kinase Variants in Hematological Malignancies: Implications for Drug Development and Opportunities for Novel Therapeutic Strategies.
Rodriguez Moncivais OJ; Chavez SA; Estrada Jimenez VH; Sun S; Li L; Kirken RA; Rodriguez G
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834019
[TBL] [Abstract][Full Text] [Related]
23. Double-edged sword of JAK/STAT signaling pathway in viral infections: novel insights into virotherapy.
Mahjoor M; Mahmoudvand G; Farokhi S; Shadab A; Kashfi M; Afkhami H
Cell Commun Signal; 2023 Oct; 21(1):272. PubMed ID: 37784164
[TBL] [Abstract][Full Text] [Related]
24. Constitutive activation and oncogenicity are mediated by loss of helical structure at the cytosolic boundary of thrombopoietin receptor mutant dimers.
Defour JP; Leroy E; Dass S; Balligand T; Levy G; Brett IC; Papadopoulos N; Mouton C; Genet L; Pecquet C; Staerk J; Smith SO; Constantinescu SN
Elife; 2023 Jun; 12():. PubMed ID: 37338955
[TBL] [Abstract][Full Text] [Related]
25. Targeting the JAK2/STAT3 signaling pathway for chronic pain.
Dai XY; Liu L; Song FH; Gao SJ; Wu JY; Li DY; Zhang LQ; Liu DQ; Zhou YQ; Mei W
Aging Dis; 2024 Feb; 15(1):186-200. PubMed ID: 37307838
[TBL] [Abstract][Full Text] [Related]
26. The prolactin receptor scaffolds Janus kinase 2 via co-structure formation with phosphoinositide-4,5-bisphosphate.
Araya-Secchi R; Bugge K; Seiffert P; Petry A; Haxholm GW; Lindorff-Larsen K; Pedersen SF; Arleth L; Kragelund BB
Elife; 2023 May; 12():. PubMed ID: 37232489
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review.
Jain NK; Tailang M; Jain HK; Chandrasekaran B; Sahoo BM; Subramanian A; Thangavel N; Aldahish A; Chidambaram K; Alagusundaram M; Kumar S; Selvam P
Front Pharmacol; 2023; 14():1135145. PubMed ID: 37021053
[TBL] [Abstract][Full Text] [Related]
28. STAM and Hrs interact sequentially with IFN-α Receptor to control spatiotemporal JAK-STAT endosomal activation.
Zanin N; Viaris de Lesegno C; Podkalicka J; Meyer T; Gonzalez Troncoso P; Bun P; Danglot L; Chmiest D; Urbé S; Piehler J; Blouin CM; Lamaze C
Nat Cell Biol; 2023 Mar; 25(3):425-438. PubMed ID: 36797476
[TBL] [Abstract][Full Text] [Related]
29. SH2 Domains: Folding, Binding and Therapeutical Approaches.
Diop A; Santorelli D; Malagrinò F; Nardella C; Pennacchietti V; Pagano L; Marcocci L; Pietrangeli P; Gianni S; Toto A
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555586
[TBL] [Abstract][Full Text] [Related]
30. Synthetic mimetics assigned a major role to IFNAR2 in type I interferon signaling.
Zoellner N; Coesfeld N; De Vos FH; Denter J; Xu HC; Zimmer E; Knebel B; Al-Hasani H; Mossner S; Lang PA; Floss DM; Scheller J
Front Microbiol; 2022; 13():947169. PubMed ID: 36118237
[TBL] [Abstract][Full Text] [Related]
31. JAK inhibition as a new treatment strategy for patients with COVID-19.
Huang J; Zhou C; Deng J; Zhou J
Biochem Pharmacol; 2022 Aug; 202():115162. PubMed ID: 35787993
[TBL] [Abstract][Full Text] [Related]
32. JAK inhibitors and COVID-19.
Levy G; Guglielmelli P; Langmuir P; Constantinescu SN
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35459733
[TBL] [Abstract][Full Text] [Related]
33. Expression analysis of IFNAR1 and TYK2 transcripts in COVID-19 patients.
Akbari M; Akhavan-Bahabadi M; Shafigh N; Taheriazam A; Hussen BM; Sayad A; Fathi M; Taheri M; Ghafouri-Fard S; Fathi M
Cytokine; 2022 May; 153():155849. PubMed ID: 35339044
[TBL] [Abstract][Full Text] [Related]
34. Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation.
Glassman CR; Tsutsumi N; Saxton RA; Lupardus PJ; Jude KM; Garcia KC
Science; 2022 Apr; 376(6589):163-169. PubMed ID: 35271300
[TBL] [Abstract][Full Text] [Related]
35. JAK2 in Myeloproliferative Neoplasms: Still a Protagonist.
Bader MS; Meyer SC
Pharmaceuticals (Basel); 2022 Jan; 15(2):. PubMed ID: 35215273
[TBL] [Abstract][Full Text] [Related]
36. Mutations in
Butzmann A; Sridhar K; Jangam D; Song H; Singh A; Kumar J; Chisholm KM; Pinsky B; Huang F; Ohgami RS
Front Oncol; 2021; 11():790481. PubMed ID: 35111674
[TBL] [Abstract][Full Text] [Related]
37. The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation.
Musella M; Galassi C; Manduca N; Sistigu A
Biology (Basel); 2021 Sep; 10(9):. PubMed ID: 34571733
[TBL] [Abstract][Full Text] [Related]
38. TYK2 in Cancer Metastases: Genomic and Proteomic Discovery.
Borcherding DC; He K; Amin NV; Hirbe AC
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439323
[TBL] [Abstract][Full Text] [Related]
39. Selective Janus kinase inhibition preserves interferon-λ-mediated antiviral responses.
Schnepf D; Crotta S; Thamamongood T; Stanifer M; Polcik L; Ohnemus A; Vier J; Jakob C; Llorian M; Gad HH; Hartmann R; Strobl B; Kirschnek S; Boulant S; Schwemmle M; Wack A; Staeheli P
Sci Immunol; 2021 May; 6(59):. PubMed ID: 33990378
[TBL] [Abstract][Full Text] [Related]
40. Janus Kinases in Leukemia.
Raivola J; Haikarainen T; Abraham BG; Silvennoinen O
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33672930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
